Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    Prevail (Wilate)
Previous Study | Return to List | Next Study

Immune Tolerance Induction in Haemophilia A Patients Using Wilate or Nuwiq (PREVAIL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03344003
Recruitment Status : Recruiting
First Posted : November 17, 2017
Last Update Posted : April 7, 2020
Sponsor:
Information provided by (Responsible Party):
Octapharma

Brief Summary:
Uncontrolled, multi-centre, non-interventional study with a prospective and a retrospective cohort, to evaluate the efficacy of Wilate or Nuwiq in achieving complete or partial immune tolerance induction (ITI) success in severe and moderate haemophilia A patients with inhibitors

Condition or disease Intervention/treatment
Hemophilia A Drug: Wilate or Nuwiq

Layout table for study information
Study Type : Observational
Estimated Enrollment : 80 participants
Observational Model: Cohort
Time Perspective: Other
Official Title: Immune Tolerance Induction in Haemophilia A Patients Using Wilate or Nuwiq - A Canadian Study
Actual Study Start Date : June 28, 2018
Estimated Primary Completion Date : December 2027
Estimated Study Completion Date : December 2027

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hemophilia

Group/Cohort Intervention/treatment
Wilate or Nuwiq prospective cohort
Evaluable haemophilia A patients with an inhibitor against FVIII enrolled prospectively
Drug: Wilate or Nuwiq
Wilate or Nuwiq administered via intravenous injection
Other Name: Wilate: Human von Willebrand factor / human coagulation factor VIII. Nuwiq: recombinant factor VIII (rhFVIII)

Wilate or Nuwiq retrospective cohort
Evaluable haemophilia A patients with an inhibitor against FVIII enrolled retrospectively
Drug: Wilate or Nuwiq
Wilate or Nuwiq administered via intravenous injection
Other Name: Wilate: Human von Willebrand factor / human coagulation factor VIII. Nuwiq: recombinant factor VIII (rhFVIII)




Primary Outcome Measures :
  1. Efficacy of Wilate or Nuwiq in achieving complete or partial immune tolerance induction (ITI) success in moderate and severe haemophilia A patients with inhibitors [ Time Frame: A maximum period of 5 years from ITI start ]
    ITI success will be determined using predefined success criteria to analyze the proportion of patients achieving complete or partial ITI success. Complete success is defined by achieving all of the following variables: 1) Inhibitor titre <0.6BU (at least 2 separate blood samplings) assessed using the modified Bethesda assay; 2) Incremental in vivo recovery (IVR) of FVIII in the normal range (≥66% of normal); 3) FVIII half-life ≥6 hours Wilate or Nuwiq infusion. Partial success is defined as two of the three criteria being met, whilst partial response is defined as one of the three criteria being met. Partial failure is defined as none of the three criteria are met, but the inhibitor titre has decreased to <5 BU; complete failure is defined as none of the three criteria are met, and the inhibitor titre is still ≥5 BU.


Secondary Outcome Measures :
  1. Time necessary to achieve complete or partial ITI success [ Time Frame: A maximum period of 5 years from ITI start ]
    Time to achieve complete or partial ITI success will be determined using predefined success criteria. Complete success is defined by achieving all of the following variables: 1) Inhibitor titre <0.6 BU (at least 2 separate blood samplings) assessed using the modified Bethesda assay; 2) Incremental IVR of FVIII in the normal range (≥66% of normal) ; 3) FVIII half-life ≥6 hours. Wilate or Nuwiq infusion. Partial success is defined as two of the three criteria being met, whilst partial response is defined as one of the three criteria being met. Partial failure is defined as none of the three criteria are met, but the inhibitor titre has decreased to <5 BU; complete failure is defined as none of the three criteria are met, and the inhibitor titre is still ≥5 BU.

  2. In case of complete or partial ITI success, duration of immune tolerance [ Time Frame: A maximum period of 5 years from ITI start ]
    Time from start of ITI success to end of study period

  3. Bleeding frequency while on Wilate or Nuwiq ITI treatment [ Time Frame: A maximum period of 5 years from ITI start ]
    Bleeding episodes occurring during the study period will be documented by the patient or their parents in a patient study diary.

  4. Association of inhibitor titres with the probability of ITI success [ Time Frame: A maximum period of 5 years from ITI start ]

    Inhibitor titre will be assessed at the start of and throughout ITI treatment, including peak inhibitor titres, with the probability of ITI success.

    ITI success will be determined using predefined success criteria. Complete success is defined by achieving all of the following variables: 1) Inhibitor titre <0.6 BU (at least 2 separate blood samplings) assessed using the modified Bethesda assay; 2) Incremental IVR of FVIII in the normal range (≥66% of normal) ; 3) FVIII half-life ≥6 hours. Wilate or Nuwiq infusion. Partial success is defined as two of the three criteria being met, whilst partial response is defined as one of the three criteria being met. Partial failure is defined as none of the three criteria are met, but the inhibitor titre has decreased to <5 BU; complete failure is defined as none of the three criteria are met, and the inhibitor titre is still ≥5 BU.


  5. Use of bypassing agents before and during ITI treatment with Wilate or Nuwiq [ Time Frame: 12 months before the start of ITI with Wilate or Nuwiq to a maximum of 5 years from starting ITI with Wilate or Nuwiq ]
    Use of bypassing agents is at the discretion of the Investigator, either to treat bleeding or to provide prophylactic therapy. As long as the patient's inhibitor level is ≥0.6 Bethesda units (BU), treatment of BEs may, in addition to FVIII treatment, require the administration of activated prothrombin complex concentrates (aPCC) or recombinant FVIIa.

  6. Use of emicizumab (Hemlibra) during ITI treatment with Wilate or Nuwiq [ Time Frame: A maximum period of 5 years from ITI start ]
    The dosing and frequency of emicizumab (Hemlibra) used is at the discretion of the Investigator. As a general guidance, the recommended dose is 3mg/kg once weekly for the first 4 weeks, followed by 1.5mg/kg once weekly, administered as a subcutaneous injection, as per the product monograph.

  7. Relapse rate following complete or partial successful ITI using Wilate or Nuwiq [ Time Frame: A maximum period of 5 years from ITI start ]
    Reoccurrence of >0.6 BU in at least 2 consecutive blood samples after having reached the prophylactic treatment phase; a further ITI initiation (re-start) with Wilate or Nuwiq is at the discretion of the Investigator.

  8. Time to relapse following complete or partial successful ITI using Wilate or Nuwiq [ Time Frame: A maximum period of 5 years from ITI start ]
    Time to reoccurrence of >0.6 BU in at least 2 consecutive blood samples after having reached the prophylactic treatment phase; a further ITI initiation (re-start) with Wilate or Nuwiq is at the discretion of the Investigator.

  9. Adherence with the ITI regimen [ Time Frame: A maximum period of 5 years from ITI start ]
    During ITI, any injections of Wilate or Nuwiq will be recorded in the patient study diary. The treating physician will review and verify the information provided by the patient.

  10. Safety: adverse drug reactions (ADRs) [ Time Frame: A maximum period of 5 years from ITI start ]
    ADRs will be documented.

  11. Safety: infection-related adverse events (AEs) [ Time Frame: A maximum period of 5 years from ITI start ]
    Any infection-related AEs, including central-line infections and infections leading to hospitalisation, will be documented.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
A total of at least 80 patients, including at least 40 evaluable haemophilia A patients with an inhibitor against FVIII in the prospective cohort and a maximum of 40 evaluable haemophilia A patients with an inhibitor against FVIII in the retrospective cohort.
Criteria

Inclusion Criteria:

  • Male patients of any age with moderate or severe haemophilia A.
  • Patients with a first occurrence of inhibitors, inhibitors refractory to previous ITI attempt(s), or relapsed inhibitors to FVIII, with an inhibitor titre of ≥0.6 BU measured on 2 separate occasions at least 2 weeks apart.
  • Informed written consent from the patient and/or the patient's parent(s) or legal guardian(s)

For patients in the prospective cohort:

  • Patients who are currently on Wilate or Nuwiq ITI, have just initiated ITI, or are planned to initiate ITI treatment with Wilate or Nuwiq.

For patients in the retrospective cohort:

  • Patients having received Wilate or Nuwiq ITI before entry into this study. Retrospective data will be collected for a maximum of 3 years before enrolment into the study. To be eligible, the following information is needed:
  • Wilate or Nuwiq treatment details (start date, dose, treatment frequency, and dose change).
  • Reliably documented bleeding frequency.
  • FVIII inhibitor titres.
  • FVIII half-life.
  • FVIII IVR.

Exclusion Criteria:

Patients who meet any of the following criteria are not eligible for the study:

  • Congenital or acquired bleeding disorders other than haemophilia A.
  • A history of hypersensitivity to blood products and/or plasma-derived FVIII concentrates.
  • Inability to speak/read English or French well enough to provide consent and adhere to the study.
  • People who are receiving other non-factor therapies, e.g. concizumab

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03344003


Contacts
Layout table for location contacts
Contact: Lidia Cosentino, PhD +1 (416) 670 1595 lidia.cosentino@octapharma.com

Locations
Layout table for location information
Canada, Alberta
Stollery children's hospital, University of Alberta Recruiting
Edmonton, Alberta, Canada
Canada, Ontario
Children's Hospital of Eastern Ontario Recruiting
Ottawa, Ontario, Canada
Hamilton Health Science center Active, not recruiting
Toronto, Ontario, Canada
Sponsors and Collaborators
Octapharma
Investigators
Layout table for investigator information
Study Director: Lidia Cosentino, PhD Octapharma
Layout table for additonal information
Responsible Party: Octapharma
ClinicalTrials.gov Identifier: NCT03344003    
Other Study ID Numbers: WIL-26
First Posted: November 17, 2017    Key Record Dates
Last Update Posted: April 7, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hemophilia A
Blood Coagulation Disorders, Inherited
Blood Coagulation Disorders
Hematologic Diseases
Coagulation Protein Disorders
Hemorrhagic Disorders
Genetic Diseases, Inborn
Factor VIII
Coagulants